

DESCRIPTION	
<b>Species Reactivity</b>	Mouse
<b>Specificity</b>	Detects mouse VE-Cadherin in direct ELISAs and Western blots. In direct ELISAs, approximately 30% cross-reactivity with recombinant human VE-Cadherin is observed.
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant mouse VE-Cadherin Asp46-Gln592 Accession # 2208309A
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.


**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	0.2 µg/mL	See Below
<b>Simple Western</b>	10 µg/mL	See Below


**DATA**

**Western Blot**




**Detection of Mouse VE-Cadherin by Western Blot.** Western blot shows lysates of mouse lung tissue and bEnd.3 mouse endothelioma cell line. PVDF membrane was probed with 0.2 µg/mL of Goat Anti-Mouse VE-Cadherin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1002) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for VE-Cadherin at approximately 120 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

**Simple Western**



**Detection of Mouse VE-Cadherin by Simple Western™.** Simple Western lane view shows lysates of mouse lung tissue, loaded at 0.2 mg/mL. Specific bands were detected for VE-Cadherin at approximately 118, 146 kDa (as indicated) using 10 µg/mL of Goat Anti-Mouse VE-Cadherin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1002). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.



**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<p><b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b></p> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

The cadherin (Ca<sup>++</sup>-dependent adherence) superfamily is a large group of membrane-associated glycoproteins that engage in homotypic, calcium-dependent, cell-cell adhesion events. The superfamily can be divided into at least five major subfamilies based on molecule gene structure, and/or extracellular (EC) and intracellular domains (1-4). Subfamilies include classical/type I, atypical/type II, and desmosomal-related cadherins (1-3). VE-Cadherin (vascular endothelial cadherin; also cadherin-5 and CD144) is a 125 kDa atypical/type II subfamily cadherin. Its subfamily classification is based principally on its genomic structure, as its physical structure is notably divergent from other type II subfamily members (2, 3). Mouse VE-Cadherin is synthesized as a 784 amino acid (aa) type I transmembrane (TM) preproprotein that contains a 24 aa signal peptide, a 21 aa prosequence, a 554 aa extracellular region (ECR), a 21 aa TM segment, and a 164 aa cytoplasmic domain (5, 6). The ECR contains five Ca<sup>++</sup>-binding cadherin domains that are approximately 105 aa in length. Cadherin domains are comprised of two β-sheets that are oriented like bread in a sandwich. Although complex, the N-terminal cadherin domain mediates *trans* interactions, while the internal domains contribute to *cis* multimerizations (7). Mouse VE-Cadherin ECR is 92%, 77%, and 73% aa identical to rat, human and porcine VE-Cadherin ECR, respectively. VE-Cadherin is involved in the maintenance of endothelial permeability. In this regard, VE-Cadherin does not initiate new blood vessel formation; it maintains it once formed. Thus, when VE-Cadherin is downregulated, cells part and permeability increases (8). Notably, VEGF is known to promote vascular leakage, and apparently does so by inducing a β-arrestin-dependent endocytosis of VE-Cadherin (9). Part of this effect may be mediated by VE-Cadherin itself which is reported to increase the membrane half-life of VEGF R2 (10). VE-Cadherin acts homotypically at sites of zonula adherens. On each expressing cell, it is proposed that VE-Cadherin first forms a trimer, which then dimerizes with a trimeric counterpart *in-trans*. Alternatively, two *cis*-dimers could act *in-trans* to generate homotypic binding (11). In addition to cell adhesion, VE-Cadherin also is reported to mediate TGF-β receptor assembly. When clustered, VE-Cadherin enhances TβRII/TβRI assembly into an active receptor complex on endothelial cells (12). VE-Cadherin is expressed on endothelial cells, trophoblast cells, endothelial progenitor cells and embryonic hematopoietic cells (5, 8, 13, 14).

**References:**

1. Patel, S.D. *et al.* (2007) *Curr. Opin. Struct. Biol.* **13**:690.
2. Vestweber, D. (2008) *Arterioscler. Thromb. Vasc. Biol.* **28**:223.
3. Vincent, P.A. *et al.* (2004) *Am. J. Physiol. Cell. Physiol.* **286**:C987.
4. Cavallaro, U. *et al.* (2006) *Exp. Cell Res.* **312**:659.
5. Breier, G. *et al.* (1996) *Blood* **87**:630.
6. Huber, P. *et al.* (1996) *Genomics* **32**:21.
7. Pokutta, S. and W.I. Weis (2007) *Annu. Rev. Cell Dev. Biol.* **23**:237.
8. Crosby, C.V. *et al.* (2005) *Blood* **105**:2771.
9. Gavard, J. and J.S. Gutkind (2006) *Nat. Cell Biol.* **8**:1223.
10. Calera, M.R. *et al.* (2004) *Exp. Cell Res.* **300**:248.
11. Hewat, E.A. *et al.* (2007) *J. Mol. Biol.* **365**:744.
12. Rudini, N. *et al.* (2008) *EMBO J.* **27**:993.
13. Kogata, N. *et al.* (2006) *Circ. Res.* **98**:897.
14. Ema, M. *et al.* (2006) *Blood* **108**:4018.